| Clinical data | |
|---|---|
| Trade names | Survanta, Alveofact |
| AHFS/Drugs.com | Monograph |
| Routes of administration |
Endotracheal |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
  (what is this?) (verify)
| |
Beractant, also known by the trade name of Survanta, is a modified bovine pulmonary surfactant containing bovine lung extract (phospholipids, neutral lipids, fatty acids, and bovine surfactant proteins), to which synthetic DPPC, tripalmitin and palmitic acid are added. The composition provides 25 mg/mL phospholipids, 0.5 to 1.75 mg/mL triglycerides, 1.4 to 3.5 mg/mL free fatty acids, and <1.0 mg/mL total surfactant proteins. As an intratracheal suspension, it can be used for the prevention and treatment of neonatal respiratory distress syndrome. Survanta is manufactured by Abbvie.
Generic form
Beraksurf is generic form of Survanta (Beractant) which is manufacturing by Tekzima.
External links
- "Beractant". Drug Information Portal. U.S. National Library of Medicine.